Patents Examined by Paul V. Ward
  • Patent number: 10363250
    Abstract: Conjugates of antifolates, releasable linkers, and drugs, and pharmaceutical compositions containing them are described. The conjugates are useful for treating diseases arising from pathogenic cell populations. Methods for treating stroll diseases are also described.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: July 30, 2019
    Assignees: Endocyte, Inc., Purdue Research Foundation
    Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Philip Stewart Low
  • Patent number: 10357493
    Abstract: Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: July 23, 2019
    Assignee: Selenity Therapeutics (Bermuda), Ltd.
    Inventor: Christopher M. Yates
  • Patent number: 10351570
    Abstract: The present invention provides novel compounds of any one of Formulae (I)-(IV), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of Formulae (I)-(IV) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: July 16, 2019
    Assignee: Kala Pharmaceuticals, Inc.
    Inventors: Winston Zapanta Ong, Pawel Wojciech Nowak, Ben C. Askew, Andrew Good
  • Patent number: 10342877
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: July 9, 2019
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
  • Patent number: 10344036
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: July 9, 2019
    Assignee: AbbVie Inc.
    Inventors: Jayanthy Jayanth, Patrick J. Marroum, Peter T. Mayer, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Ayman Allian
  • Patent number: 10344015
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilizing said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: July 9, 2019
    Assignee: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Patent number: 10344040
    Abstract: Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: July 9, 2019
    Assignees: GILEAD CONNECTICUT, INC., GENENTECH INC.
    Inventors: Antonio J. M. Barbosa, Peter A. Blomgren, Kevin S. Currie, Ravi Krishnamoorthy, Jeffrey E. Kropf, Seung H. Lee, Scott A. Mitchell, Daniel Ortwine, Aaron C. Schmitt, Xiaojing Wang, Jianjun Xu, Wendy Young, Honglu Zhang, Zhongdong Zhao, Pavel E. Zhichkin
  • Patent number: 10336730
    Abstract: The present invention provides compounds of Formula (I): (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: July 2, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, William R. Ewing, Donald J. P. Pinto, Leon M. Smith, II
  • Patent number: 10335394
    Abstract: The present invention relates to processes for preparing substances with antiviral activity, in particular the integrase inhibitors dolutegravir and cabotegravir and analogues thereof, as well as intermediates useful in the processes.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: July 2, 2019
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Nenad Maras, Lovro Selic, Anja Cusak
  • Patent number: 10336753
    Abstract: The present invention refers to novel process for the preparation of Apixaban. Further, the invention also related to a process for the preparation of intermediate of Apixaban from very basic and cheap row material i.e. Aniline which is widely commercially available. The present invention provides process for preparation of Apixaban using a different sequence of synthetic steps and does not involve use of Ullmann reaction.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 2, 2019
    Assignee: Unichem Laboratories Limited
    Inventors: Dhananjay G. Sathe, Arijit Das, Yashwant Surve, Ramdas N. Ahire
  • Patent number: 10336767
    Abstract: Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: July 2, 2019
    Assignee: Kala Pharmaceuticals, Inc.
    Inventors: Minh Ngoc Nguyen, Winston Zapanta Ong
  • Patent number: 10329306
    Abstract: Disclosed is a crystalline polymorph 1-(1-methyl-1H-pyrazol-4-yl)-N-((1R,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide, Form G, and processes for making the same.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: June 25, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Yuxin Zhao
  • Patent number: 10322105
    Abstract: A pharmaceutical composition containing ginkgolide B and an ADP receptor antagonist, a preparation method thereof and use thereof in preparation of antiplatelet drugs, wherein the ADP receptor antagonist is clopidogrel, prasugrel, ticagrelor and/or ticlopidine.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 18, 2019
    Assignee: CHENGDU BAIYU PHARMACEUTICAL CO., LTD
    Inventor: Yi Sun
  • Patent number: 10316030
    Abstract: The invention relates to crystalline salts of a heterocyclic compound, methods of their preparation, and related pharmaceutical preparations thereof. The invention further relates to methods of treatment using the crystalline salts of the invention.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: June 11, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Timothy F. Stanton, James J. Springer, Jacqueline N. Williams
  • Patent number: 10306887
    Abstract: Embodiments of the invention are directed of compositions for activation or inhibition of the Oct?2 receptor and uses thereof. The inventors have discovered that the beta adrenergic-like octopamine receptor Oct?2 serves as a key signaling molecule for ovulation and recruits protein kinase A and Ca2+/calmodulin-sensitive kinase II as downstream effectors for this activity. Oct?2R homozygous mutant females are sterile, and display normal courtship, copulation, sperm storage and post-mating rejection behavior but were unable to lay eggs.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: June 4, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS
    Inventor: Kyung-an Han
  • Patent number: 10307422
    Abstract: Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: June 4, 2019
    Assignee: USHER III INITIATIVE, INC.
    Inventors: Roland Werner Bürli, William Rameshchandra Krishna Esmieu, Christopher James Lock, Karine Fabienne Malagu, Andrew Pate Owens, William E. Harte
  • Patent number: 10301287
    Abstract: The invention relates to solid forms of cenicriviroc mesylate, methods of their preparation, pharmaceutical compositions thereof and methods of their use.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: May 28, 2019
    Assignee: Tobira Therapeutics, Inc.
    Inventors: Pasit Phiasivongsa, Martin Ian Cooper, Emma Kay Sharp
  • Patent number: 10301306
    Abstract: Compounds having Formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK3 modulation. All the variables defined herein.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: May 28, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Amy C. Hart, William J. Pitts, Harold Mastalerz, Junqing Guo, Gregory D. Brown
  • Patent number: 10301292
    Abstract: Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: May 28, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Ryo Mizojiri, Hiroshi Banno, Moriteru Asano, Daisuke Tomita, Noriyuki Nii, Hironobu Maezaki, Michiko Tawada
  • Patent number: 10285991
    Abstract: Described herein are compounds of Formula (I)-(III), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating and/or preventing diseases are also provided.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 14, 2019
    Assignee: Kala Pharmaceuticals, Inc.
    Inventors: Winston Zapanta Ong, Pawel Wojciech Nowak, Ben C. Askew, Jinsoo Kim